Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BT595 intravenous immunoglobulin replacement in primary immunodeficiency
2015-003652-52Phase 3Completed
- Sponsor
- Biotest AG
- Start
- May 2016
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of KIg10 in Immunogenetic disorder, sponsored by Biotest AG. Primary endpoint: Rate of acute serious bacterial infections. Started May 2016; status: completed.
02
Drugs
KIg10
03
Conditions
Immunogenetic disorder
Beyond the preview
Go deeper on 2015-003652-52.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003652-52.